OTTAWA, ON – INOVAIT, Canada’s image-guided therapy and artificial intelligence network, launched the first installment of its Navigating the Canadian Image-guided Therapy (IGT) Sector Series—a comprehensive market research initiative chronicling the experiences of 30 Canadian IGT companies. Drawing on data analysis and in-depth interviews with company leadership, this series provides unique insights into one of Canada’s resilient and emerging medical technology sub-sectors.
The purpose of this series is to share the knowledge and experiences of IGT founders and executives who have navigated the challenges and opportunities of the Canadian IGT sector, thus helping guide and support others who may face similar obstacles and decisions in commercializing Canadian IGT or medtech.
The series will be released in multiple installments throughout 2026, each focused on critical industry topics. Today’s first part, “Funding & Investment,” delivers actionable insights on capital access in the Canadian IGT sector.
“The report analyzes diverse funding sources, explores candid perspectives on current government funding mechanisms from company leadership, and offers strategic recommendations to address the most pressing funding issues constraining sector growth,” says Dr. Philip Boyer, lead author of the market research series and Program Manager for the Health Data Innovation Program at INOVAIT. “Key findings reveal specific gaps in the funding ecosystem that, if addressed, could unlock significant economic opportunities and position Canada as a global leader in medical innovation.”
The report was officially unveiled at INOVAIT’s Discovery Forum, the organization’s flagship annual meeting held in Ottawa, where industry leaders, investors, and policymakers gathered to discuss the future of Canadian medical technology innovation.
Interested in the report? Visit the INOVAIT website to access Part 1 of the series: www.inovait.ca/reports
